Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)

被引：0

作者：

Silverberg, Jonathan, I ^{[1
]}

Bunick, Christopher ^{[2
,3
]}

Hong, H. Chih-ho ^{[4
,5
]}

Mendes-Bastos, Pedro ^{[6
]}

Gold, Linda Stein ^{[7
]}

Costanzo, Antonio ^{[8
]}

Ibrahim, Nadia ^{[9
]}

Sancho, Cristina ^{[9
]}

Wu, Xiaoqiang ^{[9
]}

Han, Yu ^{[9
]}

Levy, Gweneth ^{[9
]}

Altman, Kathy ^{[9
]}

Eyerich, Kilian ^{[10
]}

机构：

[1] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA

[2] Yale Univ, Dept Dermatol, New Haven, CT USA

[3] Yale Univ, Program Translat Biomed, New Haven, CT USA

[4] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

[5] Prob Med Res, Surrey, BC, Canada

[6] Hosp CUF Descobertas, Dermatol Ctr, Lisbon, Portugal

[7] Henry Ford Hlth Syst, Dermatol Clin Res, West Bloomfield, MI USA

[8] Humanitas Univ, Dept Biomed Sci, Dermatol Unit, Pieve Emanuele, Italy

[9] AbbVie Inc, N Chicago, IL USA

[10] Univ Freiburg, Med Ctr, Dept Dermatol & Venerol, Freiburg, Germany

来源：

关键词：

atopic dermatitis; eczema; upadacitinib; dupilumab; Level Up;

D O I：

10.1093/bjd/ljae266.107

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

734

引用

页数：2